Skip to Content

Calcium Gluconate Injection


Dosage Form: injection, solution

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.



0.465 Elemental Calcium (CA++) mEq/mL

0.68 m0smol/L

Calcium Gluconate Injection, USP is a sterile, nonpyrogenic supersaturated solution of calcium gluconate for intravenous use only.

Each mL contains: Calcium gluconate 94 mg; calcium saccharate (tetrahydrate) 4.5 mg; water for injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (6.0 to 8.2).

Calcium saccharate provides 6% of the total calcium and stabilizes the supersaturated solution of calcium gluconate.

Each 10 mL of the injection provides 93 mg elemental calcium (Ca++) equivalent to 1 g of calcium gluconate.

The structural formual is:

Calcium Gluconate Injection - Clinical Pharmacology

Calcium is the fifth most abundant element in the body and is essential for maintenance of the functional integrity of nervous, muscular and skeletal systems, cell membranes and capillary permeability. It is also an important activator in many enzymatic reactions and is essential to a number of physiologic processes, including transmission of nerve impulses; contraction of cardiac; smooth and skeletal muscles; renal function; respiration; and blood coagulation. Calcium also plays regulatory roles in the release and storage of neurotransmitters and hormones; in the uptake and binding of amino acids; in cyanocobalamin (vitamin B12) absorption; and gastrin secretion.

Indications and Usage for Calcium Gluconate Injection

Calcium Gluconate Injection, USP is used to treat conditions arising from calcium deficiencies such as hypocalcemic tetany, hypocalcemia related to hypoparathyroidism and hypocalcemia due to rapid growth or pregnancy. It is also used in the treatment of blackwidow spider bites to relieve muscle cramping and as an adjunct in the treatment of rickets, osteomalacia, lead colic and magnesium sulfate overdosage. Calcium gluconate has also been employed to decrease capillary permeability in allergic conditions, nonthrombocytopenic purpura and exudative dermatoses such as dermatitis herpetiformis and for prurifus of eruptions caused by certain drugs. In hyperkalemia, calcium gluconate may aid in antgonizing the cardiac toxicity, provided the patient is not receiving digitalis therapy.


Calcium slats are contraindicated in patients with ventricular fibrillation or hypercalcemia. Intravenous administration of calcium is contraindicated when serum calcium levels are above normal.


For intravenous use only. Subcutaneous or intramuscular injection may cause severe necrosis and sloughing.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.



To avoid undesirable reactions that may follow rapid intravenous administration of calcium gluconate, the drug should be given slowly, e.g., approximately 1.5 mL over a period of one minute. When injected intravenously, calcium gluconate should be injected through a small needle into a large vein in order to avoid too rapid an increase in serum calcium and extravasation of calcium solution into the surrounding tissue with resultant necrosis.

Rapid injection of calcium gluconate may cause vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmias, syncope and cardiac arrest.

Because of the danger involved in simultaneous use of calcium salts and drugs of the digitalis group, a digitalized patient should not receive an intravenous injection of a calcium compound unless indications are clearly defined.

Drug Interactions

The inotropic and toxic effects of cardiac glycosides and calcium are synergistic, and arrhythmias may occur if these drugs are given together (particularly when calcium is given intravenously). Intravenous administrationn of calcium should be avoided in patients receiving cardiac glycosides; if necessary, calcium should be given slowly in small amounts.

Calciumcomplexes tetracycline antibiotics rendering them inactive. The two drugs should not be given at the same time orally nor should they be mixed for parenteral administration.

Calcium Gluconate Injection has been reported to be incompatible with intravenous solutions containing various drugs. Published data are too varied and/or limited to permit generalizations, and specialized reference should  be consulted for specific information.

Drug/Laboratory Test Interactions

Transient elevations of plasma 11-hydroxycorticosteroid levels (Glenn-Nelson technique) may occur when intravenous calcium is administered but levels return to control values for serum and urinary magnesium.


Teratogenic Effects: Pregnancy Category C - Animal reproduction studies have not been conducted with calcium gluconate. It is also not known whether calcium gluconate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Calcium gluconate should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when calcium gluconate is adminstered to a nursing woman.

Adverse Reactions

Patients may complain of tingling sensations, a sense of oppression or heat waves and a calcium or chalky taste following the intravenous administration of calcium gluconate.

Rapid intravenous injection of calcium salts may cause vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmias, syncope and cardiac arrest. Use in digitalized patients may precipitate arrhythmias.

Local neocrosis and abscess formation may occur with intramuscular injection.

Calcium Gluconate Injection Dosage and Administration

The dose is dependent on the requirements of the individual patient. Intravenous Calcium Gluconate Injection must be administered slowly.

Usual Dosage

Adults - 500 mg to 2 g (5 to 20 mL)

Pediatric patients  - 200 to 500 mg (2 to 5 mL)

Infants - Not more than 200 mg (not more than 2 mL)

Parenteral drug products should be inspected visually for particulate matter and discorloration prior to adminsitration, whenever solution and container permit.

How is Calcium Gluconate Injection Supplied

Packaged in 25 vials per tray.

Store at 20 to 25C (68 to 77F) [see USP Controlled Room Temperature]. Do not permit to freeze.

Preservative Free. Discard unused portion. Use only if solutio is clear and seal intact.

This container closure is not made with natural rubber latex.

NOTE: Supersaturated solutions are prone to precipitation. The precipitate, if present, may be dissolved by warming the vial to 60 to 80C, with occasional agitation, until the solution becomes clear. Shake vigorously. Allow to cool to room temperature before dispensing. Use injection only if clear immediately prior to use.

Fresenius Kabi USA, LLC

Lake Zurich, IL 60047


Revised: August 2015


Calcium Gluconate Injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:52584-311(NDC:63323-311)
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Inactive Ingredients
Ingredient Name Strength
# Item Code Package Description
1 NDC:52584-311-19 1 VIAL, SINGLE-DOSE in 1 BAG
1 10 mL in 1 VIAL, SINGLE-DOSE
2 NDC:52584-311-59 1 VIAL, SINGLE-DOSE in 1 BAG
2 50 mL in 1 VIAL, SINGLE-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 06/11/2015
Labeler - General Injectables & Vaccines, Inc. (108250663)
Revised: 03/2016
General Injectables & Vaccines, Inc.